Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NEWL Float 2.8 Million Volume 25 MIllion
NEWL Float 2.8 Million Volume 25 MIllion
GLUU SCAM Net Income 133K MKT CAP 547 Million Dollars WOW TALK ABOUT A PUMP AND DUMP SCAM!!!! GEESH ONLY MADE 133 THOUSAND DOLLARS AND HAS A MARKET CAP OF 547 MILLION DOLLARS Reporting this PUMP AND DUMP SCAM TO THE SEC AND FBI AND MY STATES ATTORNEY GENERALS OFFICE!!!!
NEWL Share Count Remains the Same Past 2 Weeks The company is done diluting yet volume some days is higher then the number of shares outstanding and this is happening on a daily basis with no more dilution kinda makes ya go Hmm What in the hell is going on here reminds me of PLUG traded the same way before it took off and ran like a bat out of hell
Shares Out.138.7M According to Ameritrade this number hasnt changed in the past week or 2 can anyone else verify this with their brokers??
Date Open High Low Close Volume Adj Close*
Jul 10, 2014 0.10 0.12 0.08 0.10 44,647,600 0.10
Jul 9, 2014 0.14 0.14 0.10 0.10 134,636,700 0.10
Jul 8, 2014 0.14 0.17 0.12 0.13 63,023,200 0.13
Jul 7, 2014 0.14 0.20 0.10 0.14 100,632,100 0.14
Jul 3, 2014 0.17 0.18 0.14 0.15 26,825,500 0.15
Jul 2, 2014 0.26 0.26 0.17 0.18 35,155,900 0.18
Jul 1, 2014 0.27 0.29 0.24 0.25 19,071,500 0.25
Jun 30, 2014 0.29 0.37 0.23 0.25 49,981,200 0.25
Jun 27, 2014 0.49 0.50 0.26 0.28 65,634,100 0.28
Look at those volumes some days way above the number of shares outstanding...
Can you guys Please check with your brokers for the number of shares outstanding and post it here please Thanks
GPDB Exclusive Deal With AMAZON.COM AMZM
http://finance.yahoo.com/news/amazon-com-chooses-green-polkadot-120300407.html
GPDB plans to put thousands of products "on sale," including bulk and unique bundled offerings that will lure Amazon.com's value-minded shoppers.
GPDB Exclusive Deal With AMAZON.COM AMZM
http://finance.yahoo.com/news/amazon-com-chooses-green-polkadot-120300407.html
GPDB plans to put thousands of products "on sale," including bulk and unique bundled offerings that will lure Amazon.com's value-minded shoppers.
GPDB Exclusive Deal With AMAZON.COM AMZM
http://finance.yahoo.com/news/amazon-com-chooses-green-polkadot-120300407.html
GPDB plans to put thousands of products "on sale," including bulk and unique bundled offerings that will lure Amazon.com's value-minded shoppers.
LIWA 5$ Down to .30 RSI=1 lol Just got Delisted from the Nasdaq to the Pink Sheets a 5 Billion Dollar Hedge Fund Bought 44% of the shares at over 5$ a share and still owns them!
LIWA 5$ Down to .30 RSI=1 lol Just got Delisted from the Nasdaq to the Pink Sheets a 5 Billion Dollar Hedge Fund Bought 44% of the shares at over 5$ a share and still owns them!
LIWA 5$ Down to .30 RSI=1 lol Just got Delisted from the Nasdaq to the Pink Sheets a 5 Billion Dollar Hedge Fund Bought 44% of the shares at over 5$ a share and still owns them!
AERISHORT COMPANY HAS LESS THEN 6 MONTHS CASH LEFT TO BURN 700 Million Mkt Cap For a Company that has Less then 6 Months Cash on hand Net change in cash and cash equivalents (33,806) Only 65 Million Dollars in Cash Left
Simple math here Company Burned -33.8 Million Dollars Last Qtr According to SEC Filings Company projects actually even greater cash burn going forward company has 65 Million in cash on hand
65 Million -33.8 Million= 31.2 Million in cash left next Qrt actually that qtr should be coming up
31.2 Million - 33.8 Million (Could be more) anyways leaves a Negative Cash Balance
Company has NO Revenues
Drug want be avaible till late 2015 Company dont even have enough cash to last that long!!!
Also projected sales is only 20 Million a YEAR
its a freaking eye drop company
http://www.sec.gov/Archives/edgar/data/1337553/000119312514197055/d718257d10q.htm
AERISHORT COMPANY HAS LESS THEN 6 MONTHS CASH LEFT TO BURN 700 Million Mkt Cap For a Company that has Less then 6 Months Cash on hand Net change in cash and cash equivalents (33,806) Only 65 Million Dollars in Cash Left
Simple math here Company Burned -33.8 Million Dollars Last Qtr According to SEC Filings Company projects actually even greater cash burn going forward company has 65 Million in cash on hand
65 Million -33.8 Million= 31.2 Million in cash left next Qrt actually that qtr should be coming up
31.2 Million - 33.8 Million (Could be more) anyways leaves a Negative Cash Balance
Company has NO Revenues
Drug want be avaible till late 2015 Company dont even have enough cash to last that long!!!
Also projected sales is only 20 Million a YEAR
its a freaking eye drop company
http://www.sec.gov/Archives/edgar/data/1337553/000119312514197055/d718257d10q.htm
$AERI Has LESS THEN 6 MONTHS CASH LEFT WARNING AERI 700 Million Mkt Cap For a Company that has Less then 6 Months Cash on hand Net change in cash and cash equivalents (33,806) Only 65 Million Dollars in Cash Left
Simple math here Company Burned -33.8 Million Dollars Last Qtr According to SEC Filings Company projects actually even greater cash burn going forward company has 65 Million in cash on hand
65 Million -33.8 Million= 31.2 Million in cash left next Qrt actually that qtr should be coming up
31.2 Million - 33.8 Million (Could be more) anyways leaves a Negative Cash Balance
Company has NO Revenues
Drug want be avaible till late 2015 Company dont even have enough cash to last that long!!!
Also projected sales is only 20 Million a YEAR
its a freaking eye drop company
http://www.sec.gov/Archives/edgar/data/1337553/000119312514197055/d718257d10q.htm
$COCO 40% Float Now Sold Short Was Down -70% Yesterday Chart Below Should Bounce trading under cash now
$COCO 40% Float Now Sold Short Was Down -70% Yesterday Chart Below Should Bounce trading under cash now
$COCO 40% Float Now Sold Short Was Down -70% Yesterday Chart Below Should Bounce trading under cash now
SELL SELL SELL SHORT SELL THIS WORTHLESS POS!!!! PRICE TARGET ZERO!!! THIS COMPANY IS GOING BANKRUPT YOU BAGHOLDERS GOING TO FIND OUT JUST HOW WORTHLESS ALL THAT PAPER REALLY IS WORTHLESS POS!!!!! SELL SELL SELL SHORT SELL THE BAGGIES THE HOLDERS THE BIG TIME LOSERS TAKE THEIR CASH LEAVE THEM HOLDING THE BAG!!!!! TO EAT THE LOSSES NEW LOWS COMING!!!! TIMBERRRRR GOING UNDER .30 TICK DROP TICK DROP TICK PLUNGE COMING AS THE BAGHOLDERS RUNS FOR THE EXITS WITH NO TAKERS IN SIGHT WORTHLESS POS!!!! PRICE TARGET ZERO!!!! WORTHLESS PAPER FOR SALE!!!!
$INSM Their ONLY Drug FAILED The company said just 2 months ago
http://www.cnbc.com/id/101526282
I dunno if you can even trust this company they only have 1 Drug that is in Phase 2 This Drug is for a VERY Rare Disease 700 Million Dollar market cap for a Bio Tech With ONLY 1 Drug NO Revenues Losing Millions Book Value around 3.60$ a share trading at 17.50$ looks not only over priced and way over valued with only 1 Drug in the pipeline anything goes wrong and apprently they have had ALOT of Problems with this drug and currently their is NO Cure Company also states in its SEC Filings it could take YEARS for it to Develop any drug
http://www.cnbc.comInsmed's lung infection drug fails mid-stage study, shares fall
Wednesday, 26 Mar 2014 | 7:47 AM ET
Reuters
COMMENTSStart the Discussion
(Adds details, background; updates share movement)
March 26 (Reuters) - Insmed Inc said its only experimental drug failed to meet the main goal of a mid-stage trial on patients with a form of bacterial lung infection, sending shares down 34 percent in premarket trade.
The company said the inhaled antibiotic Arikayce did not reduce bacterial density, a measure of change in infection, significantly enough in patients with treatment-resistant nontuberculous mycobacterial(NTM) lung infections.
Insmed compared the drug, in combination with a standard treatment, with a combination of placebo and the standard treatment.
This is the second setback for the company which said in July last year that Arikayce, formerly known as Arikace, did not show better results than a competing drug made by Novartis AG in a late-stage study.
Insmed said on Wednesday patients treated with Arikayce experienced a greater number of adverse events, including throat irritation, than those on placebo.
The company, however, said the adverse events were consistent with those seen in patients receiving inhaled antibiotics.
NTM lung infections are caused by a type of bacteria found in soil as well as water. An infection can cause severe lung disease characterized by cough, fever and blood in the mucus.
Insmed's shares, which were halted prior to the announcement, fell to $12.00 in premarket trade. They closed at $18.30 on the Nasdaq on Tuesday.
/id/101526282
$INSM Their ONLY Drug FAILED The company said just 2 months ago
http://www.cnbc.com/id/101526282
I dunno if you can even trust this company they only have 1 Drug that is in Phase 2 This Drug is for a VERY Rare Disease 700 Million Dollar market cap for a Bio Tech With ONLY 1 Drug NO Revenues Losing Millions Book Value around 3.60$ a share trading at 17.50$ looks not only over priced and way over valued with only 1 Drug in the pipeline anything goes wrong and apprently they have had ALOT of Problems with this drug and currently their is NO Cure Company also states in its SEC Filings it could take YEARS for it to Develop any drug
http://www.cnbc.comInsmed's lung infection drug fails mid-stage study, shares fall
Wednesday, 26 Mar 2014 | 7:47 AM ET
Reuters
COMMENTSStart the Discussion
(Adds details, background; updates share movement)
March 26 (Reuters) - Insmed Inc said its only experimental drug failed to meet the main goal of a mid-stage trial on patients with a form of bacterial lung infection, sending shares down 34 percent in premarket trade.
The company said the inhaled antibiotic Arikayce did not reduce bacterial density, a measure of change in infection, significantly enough in patients with treatment-resistant nontuberculous mycobacterial(NTM) lung infections.
Insmed compared the drug, in combination with a standard treatment, with a combination of placebo and the standard treatment.
This is the second setback for the company which said in July last year that Arikayce, formerly known as Arikace, did not show better results than a competing drug made by Novartis AG in a late-stage study.
Insmed said on Wednesday patients treated with Arikayce experienced a greater number of adverse events, including throat irritation, than those on placebo.
The company, however, said the adverse events were consistent with those seen in patients receiving inhaled antibiotics.
NTM lung infections are caused by a type of bacteria found in soil as well as water. An infection can cause severe lung disease characterized by cough, fever and blood in the mucus.
Insmed's shares, which were halted prior to the announcement, fell to $12.00 in premarket trade. They closed at $18.30 on the Nasdaq on Tuesday.
/id/101526282
Their ONLY Drug FAILED The company said just 2 months ago
http://www.cnbc.com/id/101526282
I dunno if you can even trust this company they only have 1 Drug that is in Phase 2 This Drug is for a VERY Rare Disease 700 Million Dollar market cap for a Bio Tech With ONLY 1 Drug NO Revenues Losing Millions Book Value around 3.60$ a share trading at 17.50$ looks not only over priced and way over valued with only 1 Drug in the pipeline anything goes wrong and apprently they have had ALOT of Problems with this drug and currently their is NO Cure Company also states in its SEC Filings it could take YEARS for it to Develop any drug
http://www.cnbc.comInsmed's lung infection drug fails mid-stage study, shares fall
Wednesday, 26 Mar 2014 | 7:47 AM ET
Reuters
COMMENTSStart the Discussion
(Adds details, background; updates share movement)
March 26 (Reuters) - Insmed Inc said its only experimental drug failed to meet the main goal of a mid-stage trial on patients with a form of bacterial lung infection, sending shares down 34 percent in premarket trade.
The company said the inhaled antibiotic Arikayce did not reduce bacterial density, a measure of change in infection, significantly enough in patients with treatment-resistant nontuberculous mycobacterial(NTM) lung infections.
Insmed compared the drug, in combination with a standard treatment, with a combination of placebo and the standard treatment.
This is the second setback for the company which said in July last year that Arikayce, formerly known as Arikace, did not show better results than a competing drug made by Novartis AG in a late-stage study.
Insmed said on Wednesday patients treated with Arikayce experienced a greater number of adverse events, including throat irritation, than those on placebo.
The company, however, said the adverse events were consistent with those seen in patients receiving inhaled antibiotics.
NTM lung infections are caused by a type of bacteria found in soil as well as water. An infection can cause severe lung disease characterized by cough, fever and blood in the mucus.
Insmed's shares, which were halted prior to the announcement, fell to $12.00 in premarket trade. They closed at $18.30 on the Nasdaq on Tuesday.
/id/101526282
PANW PUMP AND DUMP SCAM BUYERS BEWARE!!! COMPANY JUST REPORTED A MASSIVE -140 MILLION DOLLAR LOSS COMPANY JUST ANNOUNCED MASSIVE DILUTION OF 100 MILLION DOLLARS STOCK IS UP 10$ a share this morning on less then 50k share volume in the pre market on 77 Million Shares so wall street just added 770 Million Dollars in market cap on less then 50k share volume after the company LOSS 140 Million Dollars and announced Dilution for another 100 Million Dollars They pumping this morning SO THEY CAN DUMP PUMP AND DUMP WARNING BUYERS BEWARE THIS SCAM WANT HOLD UP NO WAY IN HELL PLUS COMPANY HAS A TON MORE LAW SUITS PENDING THAT COULD POTENTIAL BANKRUPT THE COMPANY
$AMOT Revenues up 140% Net Income up 120% Nice Divy Payment Today for Shareholders who own the stock at the Close Today May 27th
http://finance.yahoo.com/news/allied-motion-declares-quarterly-cash-183100433.html
Also Read the Latest Earnings report HUGE Growth Revenues up 140% Net Income up 120% Company Projects for Revenues to more then Double again in 2014
http://finance.yahoo.com/news/allied-motion-reports-record-results-201500704.html
$AMOT Revenues up 140% Net Income up 120%
$AMOT Nice Divy Payment Today for Shareholders who own the stock at the Close Today May 27th
http://finance.yahoo.com/news/allied-motion-declares-quarterly-cash-183100433.html
Also Read the Latest Earnings report HUGE Growth Revenues up 140% Net Income up 120% Company Projects for Revenues to more then Double again in 2014
http://finance.yahoo.com/news/allied-motion-reports-record-results-201500704.html
$AMOT Nice Divy Payment Today for Shareholders who own the stock at the Close Today May 27th
http://finance.yahoo.com/news/allied-motion-declares-quarterly-cash-183100433.html
Also Read the Latest Earnings report HUGE Growth Revenues up 140% Net Income up 120% Company Projects for Revenues to more then Double again in 2014
http://finance.yahoo.com/news/allied-motion-reports-record-results-201500704.html
$AMOT WOW 140% Revenues Growth 120% Net Income Growth!!!
http://finance.yahoo.com/news/allied-motion-reports-record-results-201500704.html
Huge Earnings and outlook they project for revenues to more then double again in 2014 along with earnings!!!! Low Float Wonder if someone dont buy out AMOT like $GE or somebody
Company just announced a Divy Payment as well for shareholders next week
$AMOT WOW 140% Revenues Growth 120% Net Income Growth!!!
http://finance.yahoo.com/news/allied-motion-reports-record-results-201500704.html
Huge Earnings and outlook they project for revenues to more then double again in 2014 along with earnings!!!! Low Float Wonder if someone dont buy out AMOT like $GE or somebody
Company just announced a Divy Payment as well for shareholders next week
$AMOT WOW 140% Revenues Growth 120% Net Income Growth!!!
http://finance.yahoo.com/news/allied-motion-reports-record-results-201500704.html
Huge Earnings and outlook they project for revenues to more then double again in 2014 along with earnings!!!! Low Float Wonder if someone dont buy out AMOT like $GE or somebody
Company just announced a Divy Payment as well for shareholders next week
NEWLCant Issue any more new shares also no more reverse stock splits per Nasdaq Rules Chart Below Volume off the charts all time lows... Time to Buy
NEWLCant Issue any more new shares also no more reverse stock splits per Nasdaq Rules Chart Below Volume off the charts all time lows... Time to Buy
NEWL HOLLY COW VOLUME 45 MILLION SHARES HOLLY COW WOW DO THEY EVEN HAVE THAT MANY SHARES OUTSTANDING??
NEWL Wow 43 Million Volume Today Holly Cow Does NEWL Even have that many shares outstanding???
DMRC Revenues Down 30% Loss 3.3 Million Ugly Outlook Company will continue to lose money and be cash flow negative for the forseable futures Revenues of only 7.2 Million Yet the Company has a market cap of 255 Million Dollars... for a company whos revenues just declined 30% and that is losing 3.3 Million a qrt thats 13.2 Million Dollars a year Hmm This stock def looks like a Bubble Short Sell
http://finance.yahoo.com/news/digimarc-reports-first-quarter-2014-200500475.html
Digimarc Reports First Quarter 2014 Financial Results
Marketwired Digimarc Corporation
April 23, 2014 4:05 PM
BEAVERTON, OR--(Marketwired - Apr 23, 2014) - Digimarc Corporation (NASDAQ: DMRC) reported financial results for the first quarter ended March 31, 2014.
First Quarter 2014 Results
Revenue for the first quarter of 2014 totaled $7.2 million compared to $10.2 million in the first quarter of 2013. The decrease was primarily due to the end of the scheduled minimum quarterly license fee payments from Intellectual Ventures (IV) in the second quarter of 2013. The comparative decline was partially offset by increased royalty revenue from other licensees.
Operating loss for the first quarter of 2014 totaled $3.3 million compared to operating income of $1.6 million in the same quarter a year-ago. The operating loss was primarily due to lower revenue and increased investment in the company's ongoing product development and sales growth initiatives, mainly focused around Digimarc Discover and Barcode.
Net loss for the first quarter of 2014 totaled $2.0 million or $(0.29) per diluted share compared to net income of $1.0 million or $0.13 per diluted share in the first quarter of 2013.
At March 31, 2014, cash, cash equivalents and marketable securities totaled $32.3 million compared to $35.0 million at December 31, 2013.
Conference Call
Digimarc will hold a conference call later today (Wednesday, April 23, 2014) to discuss these results. Management will also provide an update on market conditions and execution of strategy. Chairman and CEO Bruce Davis and CFO Charles Beck will host the call starting at 5:00 p.m. Eastern time (2:00 p.m. Pacific time). A question and answer session will follow management's presentation.
The call will be broadcast live via webcast at www.digimarc.com/investors and available for replay through May 23, 2014. The webcast will be archived and available on Digimarc's website at www.digimarc.com/investors/investor-events-and-webcasts.
For those who wish to listen to the call via telephone, please dial the telephone number below at least five minutes prior to the scheduled start time:
Number: 866-562-9934
Conference ID: 27179676
If you have any difficulty connecting with the conference call, please contact Liolios Group at 949-574-3860.
About Digimarc
Digimarc Corporation (NASDAQ: DMRC), based in Beaverton, Oregon, is a leading innovator and provider of enabling technologies that create digital identities for all forms of media and many everyday objects. The embedded Digimarc IDs are imperceptible to humans, but not to computers, networks and devices like mobile phones, which can now use cameras and microphones as sensory inputs to "see, hear and understand" the world around them within the context of their environment. Digimarc has built an extensive intellectual property portfolio with patents in digital watermarking, content identification and management, media and object discovery to enable ubiquitous computing, and related technologies. Digimarc develops solutions, licenses its intellectual property, and provides development services to business partners across a range of industries. For more information, visit www.digimarc.com.
Forward-looking Statements
With the exception of historical information contained in this release, the matters described in this release contain various "forward-looking statements." These forward-looking statements include statements and any related inferences regarding increased royalty revenue from other licensees, increased investments in product development and sales growth initiatives, and other statements identified by terminology such as "will," "should," "expects," "estimates," "predicts" and "continue" or other derivations of these or other comparable terms. These forward-looking statements are statements of management's opinion and are subject to various assumptions, risks, uncertainties and changes in circumstances. Actual results may vary materially from those expressed or implied from the statements in this release as a result of changes in economic, business and/or regulatory factors. More detailed information about risk factors that may affect actual results will be set forth in the company's Form 10-K for the year ended December 31, 2013 and in subsequent periodic reports filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's opinions only as of the date of this release. Except as required by law, Digimarc undertakes no obligation to publicly update or revise any forward-looking statements to reflect events or circumstances that may arise after the date of this release.
Digimarc Corporation
Consolidated Income Statement Information
(in thousands, except per share amounts)
(Unaudited)
Three-Month Information
March 31, March 31,
2014 2013
Revenue:
Service $ 2,988 $ 2,929
Subscription 1,412 1,384
License 2,805 5,930
Total revenue 7,205 10,243
Cost of revenue:
Service 1,414 1,403
Subscription 649 635
License 83 96
Total cost of revenue 2,146 2,134
Gross profit:
Service 1,574 1,526
Subscription 763 749
License 2,722 5,834
Total gross profit 5,059 8,109
Gross margin:
Service 53 % 52 %
Subscription 54 % 54 %
License 97 % 98 %
Percentage of gross profit to total revenue 70 % 79 %
Operating expenses:
Sales and marketing 1,879 1,277
Research, development and engineering 3,546 2,725
General and administrative 2,421 2,186
Intellectual property 534 277
Total operating expenses 8,380 6,465
Operating income (loss) (3,321 ) 1,644
Other income, net 27 29
Income (loss) before income taxes (3,294 ) 1,673
(Provision) benefit for income taxes 1,308 (702 )
Net income (loss) $ (1,986 ) $ 971
Earnings (loss) per common share:
Earnings (loss) per common share - basic $ (0.29 ) $ 0.13
Earnings (loss) per common share - diluted $ (0.29 ) $ 0.13
Weighted average common shares outstanding - basic 7,000 6,838
Weighted average common shares outstanding - diluted 7,000 7,058
Cash dividends declared per common share: $ 0.11 $ 0.11
Digimarc Corporation
Consolidated Cash Flow Information
(in thousands)
(Unaudited)
Three-Month Information
March 31, March 31,
2014 2013
Cash flows from operating activities:
Net income (loss) $ (1,986 ) $ 971
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization of property and equipment 231 158
Amortization and write-off of intangibles 308 299
Change in allowance for doubtful accounts (7 ) -
Gain on reversal of contingent merger consideration - (190 )
Stock-based compensation 1,259 1,092
Deferred income taxes (509 ) (112 )
Excess tax benefit from stock-based awards (72 ) -
Changes in operating assets and liabilities:
Trade accounts receivable, net 1,809 (228 )
Other current assets (699 ) (44 )
Other assets 84 1
Accounts payable and other accrued liabilities (317 ) (213 )
Income taxes payable 3 778
Deferred revenue (1,484 ) 832
Net cash provided by (used in) operating activities (1,380 ) 3,344
Cash flows from investing activities:
Purchase of property and equipment (117 ) (86 )
Capitalized patent costs (295 ) (228 )
Maturity of marketable securities 11,192 23,116
Purchase of marketable securities (9,266 ) (21,933 )
Net cash provided by investing activities 1,514 869
Cash flows from financing activities:
Issuance of common stock 712 -
Purchase of common stock (850 ) (648 )
Cash dividends paid (824 ) (801 )
Excess tax benefit from stock-based awards 72 -
Net cash used in financing activities (890 ) (1,449 )
Net increase (decrease) in cash and cash equivalents (1) $ (756 ) $ 2,764
Cash, cash equivalents and marketable securities at beginning of period 34,964 39,056
Cash, cash equivalents and marketable securities at end of period 32,282 40,637
(1) Net increase (decrease) in cash, cash equivalents and marketable securities $ (2,682 ) $ 1,581
Digimarc Corporation
Consolidated Balance Sheet Information
(in thousands)
(Unaudited)
March 31, December 31,
2014 2013
Assets
Current assets:
Cash and cash equivalents (2) $ 3,055 $ 3,811
Marketable securities (2) 28,120 25,851
Trade accounts receivable, net 4,036 5,838
Other current assets 2,368 1,658
Total current assets 37,579 37,158
Marketable securities (2) 1,107 5,302
Property and equipment, net 2,326 2,395
Intangibles, net 6,740 6,709
Goodwill 1,114 1,114
Deferred tax assets, net 4,519 3,949
Other assets 486 570
Total assets $ 53,871 $ 57,197
Liabilities and Shareholders' Equity
Current liabilities:
Accounts payable and other accrued liabilities $ 1,325 $ 1,560
Deferred revenue 2,690 4,218
Total current liabilities 4,015 5,778
Deferred rent and other long-term liabilities 505 496
Total liabilities 4,520 6,274
Commitments and contingencies
Shareholders' equity:
Preferred stock 50 50
Common stock 8 7
Additional paid-in capital 42,735 41,498
Retained earnings 6,558 9,368
Total shareholders' equity 49,351 50,923
Total liabilities and shareholders' equity $ 53,871 $ 57,197
(2) Aggregate cash, cash equivalents, short- and long-term marketable securities was $32,282 and $34,964 at March 31, 2014 and December 31, 2013, respectively.